To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Inclusion Criteria: * 1 Subjects with pathologically proven with relapsed or refractory lymphoma and with disease progression during or after the last treatment or no objective response confirmed after adequate treatment. * 2 Cohort 1: Subjects with Classical Hodgkin lymphoma (cHL) who had previously received at least twice systemic therapy and are resistant to PD-1 or PD-L1. * 3 Cohort 2: Subjects with B lymphocyte non-Hodgkin lymphoma (B-NHL) who had previously received at least twice systemic therapy containing anti-CD20-targeted therapy. * 4 Cohort 3：Subjects with T lymphocyte non-Hodgkin lymphoma (T-NHL) who had previously received at least one systemic therapy. * 5 Subjects with measurable lesions as defined by Lugano2014. * 6 Aged 18-75 years ; Eastern Cooperative Oncology Group (ECOG) score:0 \~ 1; Expected survival ≥3 months. * 7 Laboratory indicators meet the requirements. * 8 Subjects voluntarily joined the study and signed the informed consent form. * 9 Non-pregnant or non-breastfeeding women; Negative pregnancy subjects. Exclusion Criteria: * 1 Subjects who have developed or is currently suffering from other malignancies within 3 years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ. * 2 Subjects who have not recovered to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 due to the adverse event of prior therapy. * 3 Subjects with significant surgery or significant traumatic injury within 28 days before first injection (excluding needle biopsy or endoscopic biopsy). * 4 Subjects with long-term unhealed wounds or fractures. * 5 Subjects with the high risk of bleeding or bleeding history or subjects with bleeding event (≥Common Terminology Criteria for Adverse Events Grade 3) within 4 weeks before first injection. * 6 Subjects with arterial/venous thrombosis within 6 months. * 7 Subjects with a history of psychotropic substance abuse who cannot be withdrawn or have mental disorders. * 8 Subjects with any severe and/or uncontrolled disease. * 9 subjects with lymphoma originating from Central Nervous System, high-grade B-cell lymphoma or hemophagocytic syndrome during screening period. * 10 Subjects with violating Central Nervous System (CNS) . * 11 Subjects with allogeneic hematopoietic stem cell transplantation. * 12 Subjects with autologous hematopoietic stem cell transplantation or Chimeric Antigen Receptor T-Cell Immunotherapy(CAR-T) within 3 months before first injection. * 13 Subjects with other factors that might cause the study to be terminated halfway per the judgement of the investigator.